HEALTHSTORY 568· JUNE 24, 2026

WHO-Backed Clinical Trial to Test Remdesivir and MBP-134 Against Bundibugyo Ebolavirus in DRC

A clinical trial set to begin next week in the Democratic Republic of the Congo will test Gilead Sciences' antiviral drug remdesivir and MappBio's monoclonal antibody MBP-134 against the Bundibugyo ebolavirus, the World Health Organization…

NDNewsDialy Desk2 MIN READ

SOURCE

statnews.com

← PREVIOUS STORY 567Asia Technology Stocks Mostly Rebound After Global Rout; Samsung Gains 9%NEXT STORY 569 →Federal Judge Blocks Texas Prosecutors From Subpoenaing Transgender Patient Records at New York Hospitals

Keep reading

More from the desk.

04HEALTH

California Supreme Court rules Gilead Sciences has no legal duty to fast-track a safer HIV drug

Pharmaceutical companies do not owe patients a legal duty to speed up development of a safer drug simply because a less safe version is already on the market. That concept, called a "duty to innovate," was at the center of a case brought…

health2 MIN

15HEALTH

Trump administration shifts 340B drug program from upfront discounts to rebates, drawing hospital backlash

A federal law requires pharmaceutical manufacturers to sell discounted medicines to specific hospitals and clinics. That discount mechanism, the foundation of the 340B Drug Pricing Program, is now being reshaped. The Trump administration…

health2 MIN

41HEALTH

Senate health panel clears Trump's CDC and pandemic preparedness nominees

A Senate committee vote, meaning a panel decision that sends nominees to the full chamber for final confirmation, moved two of President Trump's public health choices forward on Thursday. Erica Schwartz, nominated to lead the Centers for…

health1 MIN

Tomorrow · 06:00

Start tomorrow already ahead.

Five stories, a two-minute read, zero noise — the world before your first coffee.

Get the 6AM brief Back to the desk